



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

The mission of CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. In addition to our fully-owned programs, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Basel, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

## PRIMARY IR CONTACT

Chris Brinzey  
Westwicke Partners  
**Phone:** 339-970-2843  
**E-mail:**  
chris.brinzey@westwicke.com

## STOCK PERFORMANCE

### CRSP (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$16.14</b>
<b>Change (%)</b>	<b>▲ 1.10 (7.31%)</b>
<b>Volume</b>	209,294
<b>52 Week Low</b>	\$11.63
<b>Market Cap</b>	\$601,562,776
<b>Rolling EPS</b>	-1.89
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	39,997,525

Data as of 06/22/17 4:00 p.m. ET



## RECENT HEADLINES & EVENTS

Jun-19-2017 - 7:30 a.m.  
CRISPR Therapeutics Announces Patent for  
CRISPR/Cas Genome Editing in China

**Date**

06/23/17 4:00  
p.m. CET

**Title**

**CRISPR Therapeutics at 22nd  
European Hematology  
Association Annual Congress  
Location MadridES**

Jun-14-2017 - 8:30 a.m.  
CRISPR Therapeutics to Present at the JMP  
Securities Life Sciences Conference

Jun-07-2017 - 8:30 a.m.  
CRISPR Therapeutics Appoints James R.  
Kasinger as General Counsel

## SEC FILINGS

**Filing Date**

**Form**

06/21/17

4

06/19/17

4

06/19/17

4

06/19/17

4

*Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources*